Shockwave Medical, Inc. (SWAV)

330,38 +0,38 (+0,12%) Alla chiusura: 04:00PM EDT

Shockwave Medical, Inc.

5403 Betsy Ross Drive
Santa Clara, CA 95054
United States
510 279 4262
https://shockwavemedical.com

Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 1.468

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Douglas E. Godshall M.B.A.	President, CEO & Director	1,69M	13,4M	1965
Mr. Daniel Hawkins	Founder and Senior Advisor	N/D	N/D	1967
Mr. John M. Adams	Co-Founder and Technical Advisor	N/D	N/D	1947
Ms. Renee M. Gaeta	Chief Financial Officer	N/D	N/D	1981
Mr. Luis Morales	Senior Vice President of Global Operations	N/D	N/D	N/D
Ms. Trinh Phung	Chief Accounting Officer, Principal Accounting Officer & VP of Finance	N/D	N/D	1978
Ms. Debbie Kaster	Vice President of Investor Relations	N/D	N/D	N/D
Mr. Hajime Tada J.D.	General Counsel & Secretary	N/D	N/D	N/D
Mr. Robert Fletcher	Senior Vice President of Marketing & Market Access	N/D	N/D	N/D
Mr. Dave Cox	Vice President of Sales	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

Governance aziendale

L'ISS Governance QualityScore di Shockwave Medical, Inc. al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 5; diritti degli azionisti: 8; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.